Tesamorelin: FDA-Approved GHRH Analog Guide

Most peptides in the growth hormone space exist in a regulatory gray zone. They're researched, discussed in anti-aging circles, and purchased through compounding pharmacies—but they're not FDA-approved drugs. Tesamorelin is the exception.

Approved in 2010 under the brand name Egrifta for HIV-associated lipodystrophy, tesamorelin is one of the few growth hormone-releasing hormone (GHRH) analogs with full FDA approval for therapeutic use. It's manufactured by Theratechnologies, a Canadian biopharmaceutical company, and has been studied in multiple Phase 3 clinical trials with published long-term safety data. Beyond its approved indication, tesamorelin has sparked interest for its effects on liver fat, cognitive function, and body composition in non-HIV populations—making it a focal point in metabolic medicine and longevity research.

This guide covers what tesamorelin is, how it works, what the clinical data shows, and where it fits in the broader peptide landscape.

Quick Facts
What Is Tesamorelin?
Mechanism of Action
Clinical Research
Off-Label Interest and Anti-Aging Applications
Safety Profile and Side Effects
Dosing and Administration
Legal Status and Availability
Frequently Asked Questions
Bottom Line
References

Quick Facts

Property	Details
Full Name	Tesamorelin acetate
Brand Name	Egrifta, Egrifta SV, Egrifta WR
Type	Synthetic GHRH analog
Amino Acids	44 (modified human GHRH 1-44)
Molecular Weight	5,135.9 Da (free base); ~5,579 Da (acetate salt)
Chemical Modification	Trans-3-hexenoic acid at N-terminus
Manufacturer	Theratechnologies Inc. (Montreal, Canada)
Half-Life	26-38 minutes (after multiple doses)
FDA Approval Date	November 10, 2010
Approved Indication	Reduction of excess abdominal fat in HIV patients with lipodystrophy
Route of Administration	Subcutaneous injection
Standard Dose	2 mg once daily

What Is Tesamorelin?

Tesamorelin is a stabilized synthetic analog of human growth hormone-releasing hormone (GHRH 1-44). While it contains all 44 amino acids found in naturally occurring GHRH, it features a crucial chemical modification: a trans-3-hexenoic acid group attached to the N-terminus (position 2). This hexenoyl modification increases the peptide's stability and protects it from cleavage by dipeptidyl aminopeptidase-4 (DPP-4), an enzyme that rapidly degrades native GHRH.

The molecular formula of tesamorelin acetate is C₂₂₁H₃₆₆N₇₂O₆₇S with an average of 7.4 acetate counter ions per peptide molecule. Its amino acid sequence is:

Trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂

Tesamorelin was discovered by Theratechnologies scientists in 1995 and underwent 15 years of development before receiving FDA approval. It's the only medication approved in the United States for the reduction of excess abdominal fat in adults with HIV who have lipodystrophy—a condition characterized by abnormal fat distribution, particularly visceral fat accumulation, often caused by antiretroviral therapy.

Unlike direct growth hormone administration, tesamorelin works through the body's natural GHRH pathway, stimulating the pituitary gland to produce endogenous growth hormone in a pulsatile manner. This preserves the negative feedback loop involving IGF-1, which may reduce the risk of adverse effects associated with exogenous GH therapy.

For context on related peptides, see CJC-1295, Sermorelin, and Ipamorelin.

Mechanism of Action

Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary gland. This binding activates adenylyl cyclase, increasing cyclic AMP (cAMP) levels within the cells, which stimulates the synthesis and pulsatile release of endogenous growth hormone.

The released GH then travels through the bloodstream to bind GH receptors on tissues throughout the body, triggering several downstream effects:

Hepatic IGF-1 Production: GH stimulates the liver to produce insulin-like growth factor-1 (IGF-1), which mediates many of GH's anabolic effects
Lipolysis: GH promotes the breakdown of triglycerides in adipose tissue, particularly visceral fat, releasing free fatty acids for energy
Protein Synthesis: GH and IGF-1 promote lean tissue growth and muscle protein synthesis
Metabolic Regulation: GH influences glucose metabolism, lipid profiles, and insulin sensitivity through complex mechanisms

What makes tesamorelin distinct from other GHRH analogs is its enhanced stability. The hexenoyl modification at the N-terminus protects the peptide from rapid enzymatic degradation by DPP-4, which normally cleaves GHRH within minutes of release. This modification extends tesamorelin's biological activity while maintaining specificity for GHRH receptors.

Importantly, the feedback inhibition of IGF-1 on GH secretion by the pituitary remains intact with tesamorelin, unlike with exogenous GH administration. This means that when IGF-1 levels rise sufficiently, they signal the pituitary to reduce GH production, preventing the supraphysiologic GH levels that can cause insulin resistance and other metabolic disturbances.

Related peptides that influence growth hormone include MK-677 (a ghrelin mimetic), GHRP-2, and GHRP-6.

Clinical Research

Tesamorelin has been studied in multiple Phase 2 and Phase 3 randomized controlled trials, primarily in HIV-infected populations but also in people with metabolic dysfunction and cognitive impairment. The following sections summarize key findings.

HIV-Associated Lipodystrophy

Tesamorelin's FDA approval was based on two pivotal Phase 3 trials: LIPO-010 (N=412) and CTR-1011 (N=404). These multi-center, double-blind, placebo-controlled studies enrolled participants from the US, Canada, and Europe, comparing tesamorelin 2 mg daily to placebo in a 2:1 ratio for 26 weeks.

Primary Results:

Visceral Adipose Tissue (VAT) Reduction: Tesamorelin decreased VAT by approximately 15-20% compared to baseline, with reductions of 19.6% in LIPO-010 and 11.7% in CTR-1011 (p<0.001 for both). Placebo groups showed minimal change.
Subcutaneous Fat Preservation: Tesamorelin did not significantly affect subcutaneous adipose tissue, meaning fat loss was targeted to visceral depots.
Sustained Effects: In extension phases where participants continued treatment for 52 weeks, VAT reductions were maintained.

A recent meta-analysis of five randomized controlled trials found that tesamorelin was associated with a mean difference of -27.71 cm² in visceral adipose tissue (95% CI [-38.37, -17.06]; P < 0.001) compared to placebo.

Muscle and Body Composition:

Beyond fat reduction, tesamorelin improved muscle parameters. In one study of adults with HIV, significant increases were observed in the total area of the rectus and psoas muscles, as well as in the lean muscle area of all four truncal muscle groups. Tesamorelin increased skeletal muscle area and density in participants who experienced clinically significant VAT reduction.

These results positioned tesamorelin as the first and only FDA-approved treatment for HIV-associated lipodystrophy.

Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)

One of the most promising areas of tesamorelin research involves its effects on liver fat. A Phase 2 randomized, double-blind, multicenter trial published in The Lancet HIV (2019) examined tesamorelin's impact on hepatic steatosis in people with HIV and non-alcoholic fatty liver disease.

Study Design:

Population: 61 HIV-infected participants with NAFLD
Intervention: Tesamorelin 2 mg daily vs. placebo for 12 months, followed by a 6-month open-label phase
Primary Endpoint: Change in liver fat measured by MRI

Key Findings:

Liver Fat Reduction: Tesamorelin reduced liver steatosis by 37% on average. Sixty percent (60%) of tesamorelin-treated participants achieved a ≥30% reduction in liver fat, compared to just 16% of placebo participants.
Fibrosis Prevention: Tesamorelin prevented progression of liver fibrosis. Among participants with baseline fibrosis, those receiving tesamorelin showed no progression, while the placebo group exhibited worsening fibrosis scores.
Safety: The treatment was well-tolerated, though two participants withdrew due to hyperglycemia.

These findings suggest tesamorelin may have therapeutic potential for NAFLD/NASH beyond the HIV population. Theratechnologies has initiated additional trials to investigate tesamorelin in NAFLD patients without HIV (ClinicalTrials.gov: NCT03375788).

Related peptides with metabolic effects include Semaglutide and Tirzepatide.

Cognitive Function

Research has explored whether tesamorelin can improve cognitive function in older adults and individuals with mild cognitive impairment (MCI). The rationale is that the somatotrophic axis—which includes GHRH, GH, and IGF-1—has potent effects on brain function, and these hormones decline with age.

Cognitive Study in Healthy Adults and MCI:

A double-blind, randomized, placebo-controlled trial published in Archives of Neurology (2012) enrolled 124 adults aged 55-87, with 60 receiving tesamorelin (1 mg daily) and 64 receiving placebo for 20 weeks.

Results:

Executive Function: Tesamorelin improved executive function (P = 0.005) as measured by Task Switching accuracy, Stroop Color-Word Interference reaction time, Self-Ordered Pointing Test accuracy, and Word Fluency.
Verbal Memory: Modest improvements were observed in short-term verbal memory.
IGF-1 Levels: Treatment increased plasma IGF-1 to levels typical of young adults (p < 0.0001), with levels remaining elevated throughout the day.
Effect in MCI: Among individuals with MCI, tesamorelin attenuated the expected functional decline, suggesting potential neuroprotective effects.

Recent HIV Study:

A more recent study in people with HIV and neurocognitive impairment showed mixed results. While IGF-1 levels increased with tesamorelin, cognitive benefits did not significantly differ between groups, though the study noted limitations including insufficient statistical power.

The cognitive research is still evolving, but early findings suggest tesamorelin may support brain function in aging populations, possibly through increased IGF-1 and improved metabolic health.

Cardiovascular and Metabolic Effects

Beyond its effects on visceral fat, tesamorelin influences several cardiovascular and metabolic parameters.

Lipid Profile Improvements:

Multiple studies have documented favorable changes in lipid profiles with tesamorelin treatment:

Triglycerides: Reductions of up to 150 mg/dL in clinical trials
Total Cholesterol: Significant decreases, with reductions in LDL cholesterol
HDL Cholesterol: The ratio of total cholesterol to HDL improved
Adiponectin: Increases in adipose tissue density correlated with higher circulating adiponectin levels, a marker of metabolic health

Cardiovascular Risk:

In a 12-month study of 60 abdominally obese volunteers, tesamorelin significantly decreased:

Carotid intima-media thickness (cIMT), a marker of atherosclerosis
C-reactive protein (CRP), an inflammatory marker
Visceral adipose tissue

A subanalysis of Phase 3 trials found that participants in the tesamorelin arm showed a modest reduction in 10-year ASCVD risk (-0.40%), though this approached but did not reach statistical significance. The reduction in cardiovascular disease risk was more pronounced among participants with higher baseline CVD risk and was driven predominantly by reductions in total cholesterol.

Glucose Metabolism:

The relationship between tesamorelin and glucose metabolism is complex. Growth hormone can induce glucose intolerance in some individuals, raising concerns about diabetes risk. However, clinical data presents a nuanced picture:

Type 2 Diabetes Study: A 12-week randomized, placebo-controlled trial in patients with type 2 diabetes found that tesamorelin did not alter insulin response or glycemic control. Fasting glucose, HbA1c, and overall diabetes control were not significantly different between groups.
HIV Population: In HIV-infected patients treated for 52 weeks, tesamorelin did not affect glucose parameters including fasting glucose, 2-hour glucose on OGTT, fasting insulin, or HbA1c.
Monitoring Recommended: Despite generally neutral effects on glucose metabolism in trials, the FDA recommends evaluating glucose status before initiating therapy and monitoring periodically during treatment, particularly in those with diabetes or prediabetes.

The preserved IGF-1 feedback loop with GHRH analogs like tesamorelin may explain why they don't produce the insulin resistance often seen with direct GH administration.

Off-Label Interest and Anti-Aging Applications

While tesamorelin is FDA-approved only for HIV-associated lipodystrophy, it has generated significant off-label interest for several reasons:

Visceral Fat Reduction in Non-HIV Populations:

Excess visceral adipose tissue is a major risk factor for metabolic syndrome, type 2 diabetes, and cardiovascular disease in the general population, not just those with HIV. Some clinicians prescribe tesamorelin off-label to patients with central obesity who haven't responded to diet and exercise alone. Clinical data in non-HIV populations remains limited compared to the HIV trials, though some studies have shown similar VAT reductions.

Body Composition Optimization:

Athletes, bodybuilders, and individuals pursuing body recomposition are interested in tesamorelin for its ability to reduce fat while preserving or increasing lean muscle mass. Unlike weight loss from caloric restriction, which often results in both fat and muscle loss, tesamorelin targets visceral fat specifically while promoting anabolic effects through GH and IGF-1.

Anti-Aging and Longevity Medicine:

Growth hormone and IGF-1 levels decline with age, a phenomenon sometimes called "somatopause." This decline is associated with increased fat mass, decreased lean mass, reduced bone density, and cognitive changes. Tesamorelin's ability to stimulate endogenous GH production while maintaining feedback regulation has positioned it as a tool in longevity medicine, alongside peptides like Epitalon and BPC-157.

Metabolic Health:

Interest extends to individuals with metabolic syndrome, fatty liver disease, and insulin resistance—conditions where visceral fat plays a central pathogenic role. As NAFLD/NASH research progresses, tesamorelin may find broader therapeutic applications.

Important Caveats:

Long-term safety data outside the HIV population remain limited
Insurance rarely covers off-label use, making it expensive for patients
Tesamorelin requires a prescription and should be used under medical supervision with appropriate monitoring

Safety Profile and Side Effects

Tesamorelin has been evaluated in multiple long-term studies, with safety data extending to 52 weeks and beyond. Overall, it has been well-tolerated in clinical trials, though like all medications, it carries potential risks.

Common Side Effects:

The most frequently reported adverse reactions include:

Injection Site Reactions: Redness, swelling, itching, or mild discomfort at the injection site (most common)
Arthralgia: Joint pain
Myalgia: Muscle pain
Pain in Extremities: Arm or leg pain
Peripheral Edema: Fluid retention, particularly in the extremities

These side effects are typically mild to moderate and often resolve with continued use or dose adjustments.

Serious Side Effects:

Less common but more serious adverse events include:

Hyperglycemia: Tesamorelin can cause elevated blood sugar and may increase the risk of type 2 diabetes. Patients should have glucose levels monitored before starting treatment and periodically thereafter.
Fluid Retention: Significant edema in some cases, which may be problematic for individuals with heart failure or kidney disease
Allergic Reactions: Serious allergic reactions, while rare, can be life-threatening and require immediate medical attention
Cancer Risk: Because GH may stimulate cell growth, there is theoretical concern about cancer risk, though clinical trials have not shown increased cancer incidence. Patients with active malignancy should not use tesamorelin.

Contraindications:

Tesamorelin should NOT be used in the following situations:

Active Malignancy: Current or recent cancer diagnosis
Pituitary Gland Conditions: History of pituitary tumor, pituitary surgery, or other pituitary gland problems
Head Trauma/Radiation: Recent head injury or history of cranial radiation therapy
Pregnancy: Tesamorelin can harm an unborn baby and is contraindicated in pregnancy
Hypersensitivity: Known allergy to tesamorelin or any component of the formulation

Warnings and Precautions:

Glucose Monitoring: Regular blood sugar checks are recommended, especially for patients with diabetes or prediabetes
IGF-1 Levels: Elevated IGF-1 has theoretical cancer risk; levels should be monitored
Cardiovascular Conditions: Use with caution in patients with heart failure or significant cardiovascular disease
Breastfeeding: It's unknown whether tesamorelin passes into breast milk; discuss risks and benefits with a healthcare provider

Drug Interactions:

Tesamorelin may interact with:

Corticosteroids: May reduce GH secretion
Cyclosporine: May alter corticosteroid metabolism
Insulin and Oral Hypoglycemic Agents: May require dose adjustments due to glucose effects

Long-Term Safety:

Studies extending to 52 weeks have shown that the prevalence of adverse events and serious adverse events during extension phases was comparable to the initial treatment phase, suggesting tesamorelin does not accumulate new safety signals with longer-term use. However, data beyond one year in large populations are limited.

Dosing and Administration

Standard Dose:

The FDA-approved dose of tesamorelin is 2 mg administered subcutaneously once daily. This dose has been used in all major clinical trials and is the only dose with established efficacy and safety data.

Timing:

Tesamorelin should be injected at approximately the same time each day, typically in the evening. GH secretion naturally peaks during sleep, and administering GHRH analogs in the evening may better align with physiologic rhythms.

Injection Site:

The recommended injection site is the abdomen. Key guidelines include:

Rotate injection sites to different areas of the abdomen
Do not inject into scar tissue, bruises, or the navel
Use a different site each day to minimize injection site reactions

Reconstitution:

Tesamorelin comes as a lyophilized powder that must be reconstituted before injection. The process varies slightly depending on the formulation:

Egrifta SV (older formulation):

Reconstitute the 2 mg vial with 2.1 mL of sterile water (provided diluent)
Roll the vial gently between your hands for 30 seconds (do not shake)
Must be reconstituted daily (single-use vial)

Egrifta WR (newer formulation, FDA-approved March 2025):

Reconstitute once weekly (not daily)
Requires less than half the administration volume of Egrifta SV
Provides enough doses for 7 days after a single reconstitution

The move from daily to weekly reconstitution with Egrifta WR significantly reduces patient burden and improves treatment adherence.

Administration Technique:

Wash hands thoroughly
Clean the injection site with alcohol
Pinch a fold of skin at the injection site
Insert the needle at a 45-90 degree angle (subcutaneous)
Inject the full dose slowly
Remove the needle and apply gentle pressure

Storage:

Before reconstitution: Store vials at room temperature (20-25°C / 68-77°F) away from light, heat, and moisture
After reconstitution: Use immediately; do not store reconstituted Egrifta SV (single-use only)
Egrifta WR after reconstitution: May be stored and used for up to 7 days

Disposal:

Use a new needle and syringe for each injection. Dispose of used needles and syringes in a puncture-resistant sharps container.

Missed Dose:

If you miss a dose, take it as soon as you remember, unless it's close to the time for your next dose. Do not double up to make up for a missed dose.

Legal Status and Availability

Prescription Status:

Tesamorelin is a prescription-only medication in the United States. It cannot be obtained legally without a valid prescription from a licensed healthcare provider.

FDA Approval:

Tesamorelin (Egrifta) received FDA approval on November 10, 2010, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is the only medication approved for this indication in the United States.

Updated formulations have since been approved:

Egrifta SV: Approved in 2019 (replaced original Egrifta)
Egrifta WR: Approved March 25, 2025 (replaces Egrifta SV), with patent protection until 2033

International Status:

In 2012, Theratechnologies withdrew its application for marketing authorization in the European Union due to insufficient long-term safety data, particularly regarding cardiovascular risk and IGF-1 levels. As a result, tesamorelin is not approved in Europe.

Availability in other countries varies; consult local regulatory authorities for specific information.

Insurance Coverage:

For the approved HIV-associated lipodystrophy indication, many insurance plans cover tesamorelin, though prior authorization is often required. Coverage criteria typically include:

Confirmed HIV diagnosis
Documented lipodystrophy with excess visceral adipose tissue
Failure of or contraindication to other interventions (diet, exercise)

For off-label uses (non-HIV visceral obesity, anti-aging, metabolic health), insurance rarely covers the medication, leaving patients to pay out-of-pocket.

Cost:

Without insurance, tesamorelin can be expensive—often several thousand dollars per month. Prices vary by pharmacy and formulation. Theratechnologies offers patient assistance programs for eligible individuals.

Compounding Pharmacies:

Some compounding pharmacies offer peptides labeled as "tesamorelin" at lower cost than the FDA-approved Egrifta formulations. However, compounded peptides are not FDA-approved and may not undergo the same quality control, purity testing, or sterility assurance as pharmaceutical-grade products. Patients considering compounded tesamorelin should discuss the risks and benefits with their healthcare provider.

Research Peptide Vendors:

Tesamorelin is sometimes sold by research peptide vendors with disclaimers that it is "not for human consumption." These products are not regulated by the FDA, are not guaranteed for purity or potency, and carry significant legal and health risks if used in humans.

Frequently Asked Questions

What's the difference between tesamorelin and sermorelin?

Both are synthetic GHRH analogs that stimulate endogenous GH production, but there are key differences:

Structure: Tesamorelin contains all 44 amino acids of human GHRH with a hexenoyl modification at the N-terminus. Sermorelin contains only the first 29 amino acids (the biologically active fragment).
Stability: Tesamorelin's chemical modification provides greater resistance to enzymatic degradation by DPP-4, potentially making it more stable and longer-acting.
FDA Approval: Tesamorelin is FDA-approved for HIV-associated lipodystrophy. Sermorelin was previously FDA-approved for pediatric growth hormone deficiency but has since been discontinued by the original manufacturer (though it remains available through compounding).
Clinical Data: Tesamorelin has more extensive clinical trial data in adults, particularly for visceral fat reduction.

Can tesamorelin help with weight loss?

Tesamorelin specifically targets visceral adipose tissue (deep belly fat) rather than overall body weight. Clinical trials show VAT reductions of 15-20%, but this doesn't always translate to dramatic changes in total body weight because:

Tesamorelin promotes lean muscle mass, which weighs more than fat
It doesn't significantly affect subcutaneous fat (the fat under the skin)
Weight loss from VAT reduction may be offset by muscle gains

If your goal is overall weight loss, peptides like Semaglutide or Tirzepatide may be more appropriate, as they work through appetite suppression and have demonstrated substantial total body weight reductions in clinical trials.

Is tesamorelin safe for long-term use?

Clinical trials have evaluated tesamorelin for up to 52 weeks with no accumulation of new safety signals over time. Long-term extension studies showed that adverse event rates during extended treatment were comparable to the initial treatment phase.

However, data beyond one year in large populations are limited. Ongoing monitoring is recommended, particularly for:

Glucose levels (risk of hyperglycemia)
IGF-1 levels (theoretical cancer risk with chronic elevation)
Injection site reactions

Patients using tesamorelin long-term should be under the care of a healthcare provider who can monitor for potential adverse effects.

Can tesamorelin increase cancer risk?

This is a common concern with any therapy that increases GH and IGF-1, as these hormones promote cell growth and proliferation. However:

Clinical trials of tesamorelin have not shown increased cancer incidence compared to placebo
The preserved feedback inhibition of IGF-1 on GH secretion may limit excessive, sustained elevations
Tesamorelin is contraindicated in patients with active malignancy

Theoretical risk remains, particularly with long-term use or in individuals with occult (undetected) malignancies. This is why patients with a history of pituitary tumors, cranial radiation, or recent cancer are not candidates for tesamorelin therapy.

Does tesamorelin require cycling?

Unlike some peptides used in bodybuilding circles, tesamorelin in clinical trials has been administered continuously without cycling. The 26-week and 52-week studies used daily dosing without interruption.

That said, some practitioners and patients choose to cycle peptides based on:

Cost considerations
Desire to minimize long-term exposure
Anecdotal reports of diminishing returns over time

There's no published data on optimal cycling protocols for tesamorelin, and the FDA-approved use is continuous daily administration.

Can I use tesamorelin with other peptides?

Tesamorelin is sometimes combined with other peptides, particularly:

Ipamorelin: A selective ghrelin mimetic that works through a different mechanism (GHRP receptor vs. GHRH receptor). Some protocols combine a GHRH analog like tesamorelin with Ipamorelin to stimulate GH release through two pathways.
BPC-157: Used for tissue repair and recovery; theoretically compatible with tesamorelin.
GHK-Cu: A copper peptide with anti-inflammatory and skin health properties; no known interactions with tesamorelin.

However, combination protocols have not been formally studied in clinical trials. Always consult with a healthcare provider before combining peptides, as interactions and cumulative risks are not well-characterized.

How does tesamorelin compare to actual growth hormone (HGH)?

Key differences:

Feature	Tesamorelin	Exogenous GH
Mechanism	Stimulates endogenous GH production via pituitary	Provides synthetic GH directly
Pulsatility	Preserves natural pulsatile GH release	Provides steady-state levels
Feedback Loop	IGF-1 feedback remains intact	Bypasses negative feedback
Dosing	Once daily subcutaneous injection	Multiple injections per week
Cost	Expensive, but generally less than GH	Very expensive
FDA Approval	Approved for HIV lipodystrophy	Approved for GH deficiency, other conditions
Side Effects	Generally milder; less risk of insulin resistance	Higher risk of edema, insulin resistance, joint pain

Tesamorelin is often considered a more physiologic approach because it works through the body's natural regulatory mechanisms rather than overwhelming them with exogenous hormone.

Can I get tesamorelin from a compounding pharmacy?

Yes, some compounding pharmacies offer tesamorelin at lower cost than brand-name Egrifta. However:

Compounded peptides are not FDA-approved
Quality, purity, and potency may vary between compounders
Sterility and contamination risk may be higher
Insurance rarely covers compounded versions

If considering compounded tesamorelin, choose a reputable pharmacy that provides certificates of analysis (COA) from third-party laboratories verifying peptide purity and concentration.

Is tesamorelin legal to use for anti-aging?

Tesamorelin is a prescription medication, and physicians in the United States may prescribe FDA-approved drugs for off-label uses at their discretion. This means a doctor can legally prescribe tesamorelin for anti-aging, body composition, or other off-label purposes if they believe it's medically appropriate.

However, this doesn't mean insurance will cover it, and patients should be fully informed about:

Limited data in non-HIV populations
Potential risks and side effects
Out-of-pocket costs

Prescribing controlled substances or medications for purposes deemed medically inappropriate can have legal consequences for physicians, so responsible providers will carefully evaluate whether off-label use is justified.

Bottom Line

Tesamorelin occupies a unique position in the peptide landscape: it's an FDA-approved GHRH analog with solid clinical trial data demonstrating efficacy for visceral fat reduction in HIV-associated lipodystrophy. Unlike many peptides discussed in longevity and biohacking communities, tesamorelin has been through the rigorous FDA approval process, with published safety data extending to 52 weeks.

The research is compelling. Reductions of 15-20% in visceral adipose tissue, improvements in liver fat, preservation or increase in lean muscle mass, and favorable effects on lipid profiles make tesamorelin a powerful tool for metabolic health. Emerging data on cognitive function and cardiovascular markers add to its appeal beyond the approved indication.

But there are caveats. Tesamorelin is expensive, particularly for off-label use. Long-term safety data in non-HIV populations are limited. The risk of glucose intolerance and theoretical cancer risk with chronic GH/IGF-1 elevation require monitoring. And while the hexenoyl modification increases stability, the peptide still has a short half-life and requires daily subcutaneous injections (or weekly reconstitution with the newer Egrifta WR formulation).

For individuals with HIV-associated lipodystrophy, tesamorelin represents the gold standard treatment with no FDA-approved alternatives. For those exploring off-label use—whether for stubborn visceral fat, metabolic syndrome, or anti-aging applications—tesamorelin is a scientifically backed option, but one that should be approached with medical supervision, realistic expectations, and an understanding of the cost-benefit trade-offs.

As research continues, particularly in NAFLD/NASH and broader metabolic populations, tesamorelin's role may expand. For now, it remains one of the most well-characterized peptides in the GH secretagogue space, bridging the gap between research-stage compounds and pharmaceutical-grade therapeutics.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Tesamorelin is a prescription medication that should only be used under the supervision of a qualified healthcare provider. The information presented here is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a licensed physician before starting any new medication or supplement, especially if you have underlying health conditions or are taking other medications. Off-label use of prescription medications carries risks that should be thoroughly discussed with a healthcare professional.

References

Mayo Clinic. (n.d.). Tesamorelin (subcutaneous route) - Side effects & dosage. Retrieved from https://www.mayoclinic.org/drugs-supplements/tesamorelin-subcutaneous-route/description/drg-20074632
Stanley TL, Falutz J, Mamputu JC, Grinspoon SK. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV, 6(12), e821-e830. https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(19)30338-8/abstract
Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 53(3), 311-322. https://pmc.ncbi.nlm.nih.gov/articles/PMC3218714/
Koutkia P, Canavan B, Breu J, Grinspoon S. (2004). Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation. Journal of Clinical Endocrinology & Metabolism, 89(5), 2154-2160.
Theratechnologies Inc. (2025). EGRIFTA WR (tesamorelin for injection) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf
Baker LD, Barsness SM, Borson S, et al. (2012). Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology, 69(11), 1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/
Falutz J, Allas S, Blot K, et al. (2010). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 362(23), 2188-2198. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. (2014). Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology & Metabolism, 96(1), 150-158. https://pmc.ncbi.nlm.nih.gov/articles/PMC3038486/
Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. (2011). Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. Journal of Clinical Investigation, 122(11), 4172-4189.
Drugs.com. (2025). Egrifta WR (tesamorelin) FDA Approval History. https://www.drugs.com/history/egrifta-wr.html
PubChem. (n.d.). Tesamorelin. National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
DrugBank Online. (n.d.). Tesamorelin: Uses, Interactions, Mechanism of Action. https://go.drugbank.com/drugs/DB08869
Erlandson KM, Jiang Y, Debanne SM, McComsey GA. (2016). Effects of tesamorelin on neurocognitive function in HIV-infected adults with excess abdominal fat: a randomized clinical trial. AIDS Research and Human Retroviruses, 32(7), 657-664.
Guaraldi G, Stentarelli C, Zona S, et al. (2015). The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. HIV Medicine, 16(7), 445-448.
Lake JE, Stanley TL, Apovian CM, et al. (2017). Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clinical Infectious Diseases, 64(10), 1422-1429.
Vance DE, Fazeli PL, Ball DA, Slater LZ, Ross LA. (2014). Cognitive functioning and driving simulator performance in middle-aged and older adults with HIV. Journal of the Association of Nurses in AIDS Care, 25(2), 120-126.
Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ. (2001). Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-PEG), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. Journal of Clinical Endocrinology & Metabolism, 86(7), 3304-3310.
Aidsmap. (2019). Tesamorelin reduces liver fat and fibrosis progression in people with HIV and non-alcoholic fatty liver disease. https://www.aidsmap.com/news/nov-2019/tesamorelin-reduces-liver-fat-and-fibrosis-progression-people-hiv-and-non-alcoholic
Fitch K, Abbara S, Lee H, et al. (2012). Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome. AIDS, 26(5), 587-597.
Stanley TL, Chen ML, Goodrich AL, et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380-389. https://jamanetwork.com/journals/jama/fullarticle/1889139
Falutz J, Potvin D, Mamputu JC, et al. (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLOS ONE, 12(6), e0179538. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0179538
MedlinePlus. (2023). Tesamorelin Injection. U.S. National Library of Medicine. https://medlineplus.gov/druginfo/meds/a611035.html
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tesamorelin. https://www.ncbi.nlm.nih.gov/books/NBK548730/
Ding Y, Wang Y, Zhang W, et al. (2024). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology. https://pubmed.ncbi.nlm.nih.gov/41545261/
Theratechnologies Inc. About Us - Our History. https://www.theratech.com/about-theratechnologies/our-history/

Table of Contents